William T. Clarke

William T. Clarke

Auto-generated profile, based on publicly available information

William T. Clarke

Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2019 in World Journal of Gastroenterology
Verified
Journal Article
Open access
WCWilliam T Clarke
William T Clarke
JFJoseph Feuerstein
Joseph Feuerstein
Patients with long-standing inflammatory bowel disease (IBD) involving at least 1/3 of the colon are at increased risk for colorectal cancer (CRC). Advancements in CRC screening and surveillance and improved treatment of IBD has reduced CRC incidence in patients with ulcerative colitis and Crohn's colitis. Most cases of CRC are thought to arise from dysplasia, and recent evidence suggests that the majority of dysplastic lesions in patients with IBD are visible, in part thanks to advancements in high definition colonoscopy and chromoendoscopy. Recent practice guidelines have supported the use of chromoendoscopy with targeted biopsies of visible lesions rather than traditional random biopsies. Endoscopists are encouraged to endoscopically resect visible dysplasia and only recommend surgery when a complete resection is not possible. New technologies such as virtual chromoendoscopy are emerging as potential tools in CRC screening. Patients with IBD at increased risk for developing CRC should undergo surveillance colonoscopy using new approaches and techniques.

15 March 2007 in Cell Motility
Verified
Journal Article
Closed access
PDF file
JBJanine M. Bekker
Janine M. Bekker
JCJessica R. Colantonio
Jessica R. Colantonio
ASAndrew Stephens
Andrew Stephens
WCW. Thomas Clarke
W. Thomas Clarke
SKStephen J. King
Stephen J. King
RCRachelle Hope Crosbie
Rachelle Hope Crosbie

1 August 2010 in Journal of Cell Science
Verified
Journal Article
Open access
PDF file
WCW. Thomas Clarke
W. Thomas Clarke
BEBen Edwards
Ben Edwards
KMKarl J. A. McCullagh
Karl J. A. McCullagh
MKMatthew W. Kemp
Matthew W. Kemp
CMCatherine Moorwood
Catherine Moorwood
KDKay Davies
Kay Davies
Syncoilin is an atypical type III intermediate filament (IF) protein, which is expressed in muscle and is associated with the dystrophin-associated protein complex. Here, we show that syncoilin is expressed in both the central and peripheral nervous systems. Isoform Sync1 is dominant in the brain, but isoform Sync2 is dominant in the spinal cord and sciatic nerve. Peripherin is a type III IF protein that has been shown to colocalise and interact with syncoilin. Our analyses suggest that syncoilin might function to modulate formation of peripherin filament networks through binding to peripherin isoforms. Peripherin is associated with the disease amyotrophic lateral sclerosis (ALS), thus establishing a link between syncoilin and ALS. A neuronal analysis of the syncoilin-null mouse (Sync−/−) revealed a reduced ability in accelerating treadmill and rotarod tests. This phenotype might be attributable to the impaired function of extensor digitorum longus muscle and type IIb fibres caused by a shift from large- to small-calibre motor axons in the ventral root.

1 June 2018 in Clinical Immunology
Verified
Journal Article
Closed access
WCWilliam T. Clarke
William T. Clarke
SAShreya S. Amin
Shreya S. Amin
Konstantinos PapamichaelKonstantinos Papamichael
Konstantinos Papamichael
JFJoseph D. Feuerstein
Joseph D. Feuerstein
ACAdam S. Cheifetz
Adam S. Cheifetz

7 October 2010 in Blood
Verified
Journal Article
Closed access
WCW. Thomas Clarke
W. Thomas Clarke
PMPeter W. Marks
Peter W. Marks

27 September 2019 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
PDF file
WCWilliam T Clarke
William T Clarke
Konstantinos PapamichaelKonstantinos Papamichael
Konstantinos Papamichael
NCNiels Vande Casteele
Niels Vande Casteele
KGKatharine A Germansky
Katharine A Germansky
JFJoseph D Feuerstein
Joseph D Feuerstein
ACAdam S Cheifetz
Adam S Cheifetz
Dear Editor: